News

European RAID Score Gives Novel Patient-Derived Outcome Measure


 

PARIS — Pain is paramount to rheumatoid arthritis patients, according to a European League Against Rheumatism survey of 505 RA patients in 10 European countries. The survey was reported by Dr. Tore K. Kvien at the annual European Congress of Rheumatology.

The finding came from a new measure, the Rheumatoid Arthritis Impact of Disease (RAID) score, created by a EULAR task force to make up for the deficiencies in the current widely used indices of disease activity—for example, the Disease Activity Score—which don't include all of the outcomes patients deem important, such as fatigue, added Dr. Kvien, professor of rheumatology at the University of Oslo and editor of the Annals of Rheumatic Diseases.

The RAID score began with a group of 10 patients who developed a list of 17 domains important to patients with RA. This list was trimmed to 7 through a subsequent survey in which 10 patients from each of 10 European countries ranked the 17 domains.

Next, 505 RA patients in 10 countries were asked to rank the relative importance of the seven domains. Pain got 23 points; function, 16; fatigue, 16; emotional well-being, 11; sleep, 11; coping, 11; and physical well-being, 11. The weighted values were unaffected by disease duration or severity level, meaning the weighting system has a desirably high generalizability.

Dr. Kvien then relied upon an extensive review of the psychometric literature and expert opinion to create the RAID questionnaire, which includes rating scales and other assessments addressing each of the seven weighted domains.

The RAID score is currently undergoing a 12-country validation study that will refine the final wording choices. After that, physicians are likely to increasingly encounter RAID as a prespecified end point in clinical trials.

Recommended Reading

Don't Be Fooled by Normal Serum Urate in Acute Gout
MDedge Rheumatology
Custom-Made Foot Orthotics Relieve Some Arthritis Pain
MDedge Rheumatology
New B-Cell Depleting Agent Is Well Tolerated : TRU-015 resulted in ACR20 improvement in half of 36 patients studied; 25% had ACR50 responses.
MDedge Rheumatology
Infliximab Plus Combo DMARDs Prevents Progression in Early RA
MDedge Rheumatology
Switch Drug Class After Anti-TNF Efficacy Failure
MDedge Rheumatology
Obesity Does Not Hamper New Knees
MDedge Rheumatology
Combo Useful in Methotrexate Failure
MDedge Rheumatology
Factors Predict Remission With DMARD Use
MDedge Rheumatology
IL-1 Blocker Shows Promise in Refractory Gout : Rilonacept resulted in a 75% improvement in pain scores in 5 of 10 patients after 6 weeks of injections.
MDedge Rheumatology
Allopurinol, Benzbromarone Both Effective in High Doses
MDedge Rheumatology